跳至主要内容
临床试验/NCT06063317
NCT06063317
终止
1 期

A Phase I, Dose Escalation and Dose Expansion, Safety and Tolerability Study of onCARlytics (CF33-CD19), Administered Intravenously or Intratumorally in Combination With Blinatumomab in Adults With Advanced or Metastatic Solid Tumors (OASIS)

Imugene Limited8 个研究点 分布在 1 个国家目标入组 25 人2023年10月2日

概览

阶段
1 期
干预措施
Hydroxyurea
疾病 / 适应症
Solid Tumor, Adult
发起方
Imugene Limited
入组人数
25
试验地点
8
主要终点
All Treatment Arms - Incidence and severity of Adverse Events
状态
终止
最后更新
上个月

概览

简要总结

This is an open-label, dose escalation and dose expansion, multi-center phase I study evaluating the safety and tolerability of CF33-CD19 administered intravenously (IV) or intratumorally (IT) in combination with blinatumomab and with or without hydroxyurea in adults with advanced or metastatic solid tumors.

详细描述

CF33-CD19, a novel chimeric orthopoxvirus, will be administered as a monotherapy or in combination with blinatumomab and with or without hydroxyurea to assess the safety and efficacy of the treatment regimens as well as immunological changes in the tumour microenvironment. Subjects eligible for treatment include those with any metastatic or advanced solid tumor who have documented radiological progression per RECIST following at least two prior lines of therapy. All enrolled monotherapy subjects will be treated with CF33-CD19 on Day 1 and 8 of Cycle 1 and then on Day 1 of each 21-day cycle thereafter. Subjects treated with the combination regimen will receive CF33-CD19 on Days 1 and 15 of each 28-day cycle. In addition, they will receive blinatumomab as a 7-day continuous infusion from Days 2-9 and Days 16-23 of each cycle.

注册库
clinicaltrials.gov
开始日期
2023年10月2日
结束日期
2026年2月2日
最后更新
上个月
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Sponsor

入排标准

入选标准

  • Written informed consent from subject or legally authorized representative.
  • Age ≥ 18 years old on the date of consent.
  • Life expectancy of at least 3 months.
  • Any histologically or cytologically confirmed advanced or metastatic solid tumor with documented radiological progression per RECIST v1.
  • Eligible subjects must have received at least two prior lines of approved therapies, including targeted therapies, for which they are eligible and failed or relapsed on or after that treatment.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 -
  • At least one measurable lesion as defined by RECIST v1.1 criteria.
  • Adequate renal function.
  • Adequate hepatic function.
  • Adequate hematologic function.

排除标准

  • Prior treatment with a poxvirus based oncolytic virus or a bispecific CD19-directed CD3 T-cell engager.
  • Continuous systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalents) or other immunosuppressive medications within 4 weeks prior to first dose of study treatment.
  • Any radiation within 2 weeks of start of study treatment.
  • Active autoimmune disease.
  • Current or history of severe skin disease with open wounds.
  • History of (non-infectious) pneumonitis / interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease.
  • History of pancreatitis.
  • Prior allogeneic tissue/organ transplant or other medical conditions requiring ongoing treatment with immunosuppressive drugs or any condition resulting in a systemic immunosuppressed state.
  • Medical history of central nervous system (CNS) metastases unless the subject has completed definitive treatment for the CNS lesions with whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS) and are neurologically stable, asymptomatic, and off corticosteroids for at least 2 months prior to first dose.
  • History of documented congestive heart failure (New York Heart Association \[NYHA\] class II - IV), unstable angina, poorly controlled hypertension, clinically significant valvular heart disease or high-risk uncontrolled arrhythmias.

研究组 & 干预措施

CF33-CD19 IV Administration in Combination with Blinatumomab and Hydroxyurea

干预措施: Hydroxyurea

CF33-CD19 IV Administration in Combination with Blinatumomab and Hydroxyurea

干预措施: CF33-CD19 IV Combination

CF33-CD19 IV Administration in Combination with Blinatumomab and Hydroxyurea

干预措施: Blinatumomab

CF33-CD19 IT Administration Monotherapy

干预措施: CF33-CD19 IT Monotherapy

CF33-CD19 IV Administration Monotherapy

干预措施: CF33-CD19 IV Monotherapy

CF33-CD19 IT Administration in Combination with Blinatumomab

干预措施: CF33-CD19 IT Combination

CF33-CD19 IT Administration in Combination with Blinatumomab

干预措施: Blinatumomab

CF33-CD19 IV Administration in Combination with Blinatumomab

干预措施: CF33-CD19 IV Combination

CF33-CD19 IV Administration in Combination with Blinatumomab

干预措施: Blinatumomab

CF33-CD19 IT Administration in Combination with Blinatumomab and Hydroxyurea

干预措施: CF33-CD19 IT Combination

CF33-CD19 IT Administration in Combination with Blinatumomab and Hydroxyurea

干预措施: Blinatumomab

CF33-CD19 IT Administration in Combination with Blinatumomab and Hydroxyurea

干预措施: Hydroxyurea

结局指标

主要结局

All Treatment Arms - Incidence and severity of Adverse Events

时间窗: From first dose of study drug through 30 days following the last dose of study treatment

Adverse events will be graded according to CTCAE v5.0.

Monotherapy Treatment Arms - Determination of RP2D to apply to Dose Escalation Combination Phase as supported by immune response as seen in cytokines

时间窗: From first dose of study drug through treatment discontinuation, an average of 6 months

Change in cytokine levels in peripheral blood pre and post dose

Monotherapy Treatment Arms - Determination of the Recommended Phase 2 Dose (RP2D) to apply to Dose Escalation Combination Phase as supported by immune response as seen in lymphocyte subsets

时间窗: From first dose of study drug through treatment discontinuation, an average of 6 months

Change in lymphocyte subset expression in tumor tissue and peripheral blood pre and post dose

Monotherapy Treatment Arms - Determination of RP2D to apply to Dose Escalation Combination Phase as supported by anti-tumor activity

时间窗: From first dose of study drug through treatment discontinuation, an average of 6 months

Stable Disease and Response (PR and CR) based on RECIST v1.1 and iRECIST v1.0.

次要结局

  • Combination Treatment Arms - Determination of the Recommended Phase 2 Dose (RP2D) for CF33-CD19 + blinatumomab + hydroxyurea combination as supported by immune response as seen in lymphocyte subsets(From first dose of study drug through treatment discontinuation, an average of 6 months)
  • Combination Treatment Arms - Determination of RP2D for CF33-CD19 + blinatumomab + hydroxyurea combination as supported by immune response as seen in cytokines(From first dose of study drug through treatment discontinuation, an average of 6 months)
  • Combination Treatment Arms - Determination of RP2D for CF33-CD19 + blinatumomab + hydroxyurea combination as supported by anti-tumor activity(From first dose of study drug through treatment discontinuation, an average of 6 months)
  • All Treatment Arms - Overall Response Rate(From first dose of study drug through treatment discontinuation, an average of 6 months)
  • All Treatment Arms - Progression Free Survival(From first dose of study drug through treatment discontinuation, an average of 6 months)
  • All Treatment Arms - Duration of Response(From first dose of study drug through treatment discontinuation, an average of 6 months)
  • All Treatment Arms - Disease Control Rate(From first dose of study drug through treatment discontinuation, an average of 6 months)

研究点 (8)

Loading locations...

相似试验